Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Joshua Yang

Pediatric Endocrinology Orlando, FL Medical Doctor

NPI 1588677876 CMS profile 71345

60 W Gore St, 2Nd Floor, Orlando, FL 32806

Open in the dashboard

General payments

$845,809

1,400 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$223,017 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Joshua Yang of Orlando, FL is reported in the CMS Open Payments database as having received $845,809 across 1,400 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $223,017 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 99th percentile of Pediatric Endocrinology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $397,851 530
2024 General $234,902 315
2023 General $132,400 258
2022 General $47,178 169
2021 General $4,796 32
2020 General $10,743 26
2019 General $17,938 70

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Joshua Yang
  • Pediatric Endocrinology median
  • Middle half of Pediatric Endocrinology
  • National median

In program year 2025, general payments to Joshua Yang were reported at $397,851. Among 971 Pediatric Endocrinology profiles paid that year, the median was $293 and the middle half received between $106 and $1,640.

Show as a table
Year Joshua Yang Pediatric Endocrinology median Middle half National median
2019 $17,938 $196 $68–$845 $163
2020 $10,743 $124 $37–$722 $114
2021 $4,796 $134 $35–$691 $132
2022 $47,178 $177 $47–$726 $149
2023 $132,400 $236 $75–$887 $160
2024 $234,902 $259 $91–$979 $164
2025 $397,851 $293 $106–$1,640 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Ascendis Pharma, Inc. $180,135 343 payments
  2. Kyowa Kirin, Inc. $176,402 293 payments
  3. Sanofi-Aventis U.S. LLC $171,919 128 payments
  4. AbbVie, Inc. $110,757 147 payments
  5. Novo Nordisk Inc $75,800 106 payments
  6. Tolmar, Inc. $45,831 73 payments
  7. Alexion Pharmaceuticals, Inc. $33,434 72 payments
  8. CutisPharma, Inc. $16,873 21 payments
  9. Sanofi US Services Inc. $10,273 1 payment
  10. TOLMAR Pharmaceuticals, Inc. $7,923 15 payments
  11. Other $16,461 201 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $599,020 232 payments
  2. Travel and Lodging $132,827 514 payments
  3. Consulting Fee $80,976 45 payments
  4. Food and Beverage $32,382 592 payments
  5. Education $604 17 payments
Products named General payments · program years 2019–2025
  1. TZIELD $169,628 121 payments
  2. SKYTROFA $158,035 310 payments
  3. LUPRON DEPOT Endocrinology $92,641 124 payments
  4. Sogroya $67,966 91 payments
  5. FENSOLVI $53,394 82 payments
  6. Crysvita fibroblast growth factor 23 (FGF23) blocking antibody. $46,149 82 payments
  7. CRYSVITA Fibroblast Growth Factor 23 Fgf23 Blocking Antibody $44,835 68 payments
  8. STRENSIQ $20,379 43 payments
  9. LUPRON DEPOT Endocrinology $10,438 16 payments
  10. TRIPTODUR $7,860 16 payments
  11. Other $21,119 238 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

1,400 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pediatric Endocrinology in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record